Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Regulatory legal settlement

Abbott $385M Baby Formula Contamination Settlement

Analysis based on 7 articles · First reported Sep 14, 2026 · Last updated Sep 15, 2026

Sentiment
-10
Attention
4
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The settlement removes a major legal overhang for Abbott Laboratories at a modest cost relative to its balance sheet, likely limiting negative pressure on the stock while keeping reputational and regulatory scrutiny on its nutrition division. Broader food-safety and infant-formula manufacturers may face heightened compliance expectations and potential liability exposure, a mild negative for the sector.

healthcare food and beverage insurance

Abbott Laboratories agreed to pay approximately $385 million to resolve federal and state civil allegations that it sold contaminated powdered infant formula to government nutrition programs between January 2018 and December 2022. The United States — United States Department of Justice announced the settlement, under which Abbott will pay $348.7 million to the federal government and $36.3 million to state Medicaid and WIC programs. The government alleged that Abbott manufactured formula at facilities in Sturgis, United States — Michigan, and Casa Grande, United States — Arizona, under conditions that failed statutory, regulatory, and contractual requirements, including recurring roof leaks, damaged spray dryers, skipped bacterial testing, and withheld contamination records. The Sturgis plant, the largest infant formula facility in the country, was shut down in February 2022 after four infants fell ill with Cronobacter sakazakii, reportedly contributing to two deaths, and the closure worsened a nationwide formula shortage. Three former Abbott employees, Austin Scott, Kristine Cooper, and Loren Cooper, filed a qui tam False Claims Act lawsuit in 2022 and will collectively receive $69 million from the federal recovery. The settlement includes no admission or finding of fault or liability, and Abbott said no unopened distributed formula ever tested positive for Cronobacter sakazakii. The government closed its criminal investigation into the matter. In August, Abbott separately agreed to pay $670 million to settle lawsuits alleging it hid the risk that its premature-infant formula could cause a deadly bowel disease.

70 Abbott Laboratories recalled infant formula
55 United States filed complaint Abbott Laboratories
50 Austin Scott filed lawsuit Abbott Laboratories
50 Kristine Cooper filed lawsuit Abbott Laboratories
50 Loren Cooper filed lawsuit Abbott Laboratories
40 Abbott Laboratories agreed to pay
stock
Abbott is the central party, paying about $385 million to settle False Claims Act allegations over contaminated infant formula without admitting fault. The resolution removes legal uncertainty but keeps reputational and regulatory risk tied to its nutrition business.
Importance 100.0 Sentiment -15.0
govactor
The DOJ announced and negotiated the settlement, resolving civil claims against Abbott and closing its criminal investigation.
Importance 70.0 Sentiment 5.0
cnt
The federal government receives $348.7 million and filed the complaint in intervention alleging Abbott submitted false claims to government programs.
Importance 65.0 Sentiment 5.0
govactor
FDA inspectors found unsanitary conditions and Cronobacter sakazakii strains at the Sturgis plant, and the agency gained five-year oversight of the facility under a consent decree.
Importance 45.0 Sentiment 0.0
govactor
USDA funds the WIC program that purchased the formula at issue, and its Inspector General criticized the plant conditions as unacceptable.
Importance 30.0 Sentiment 0.0
loc
United States — Michigan hosts the Sturgis plant at the center of the contamination allegations and receives part of the $36.3 million state settlement.
Importance 30.0 Sentiment 0.0
govactor
The CDC investigated the infant illnesses and reportedly said there was no definitive link between the Sturgis facility and the clinical cases.
Importance 25.0 Sentiment 0.0
per
The Associate Attorney General stated that no company should gamble with infant health and safety through unsanitary conditions.
Importance 20.0 Sentiment 0.0
per
A former Abbott employee and whistleblower who filed the qui tam suit and shares in the $69 million federal recovery.
Importance 20.0 Sentiment 0.0
per
A former Abbott employee and whistleblower who filed the qui tam suit and shares in the $69 million federal recovery.
Importance 20.0 Sentiment 0.0
per
A former Abbott employee and whistleblower who filed the qui tam suit and shares in the $69 million federal recovery.
Importance 20.0 Sentiment 0.0
loc
United States — Arizona hosts the Casa Grande facility cited among the plants with alleged manufacturing deficiencies.
Importance 15.0 Sentiment 0.0
per
The Acting Deputy Attorney General called the settlement a victory for American families and warned of decisive action against misconduct.
Importance 15.0 Sentiment 0.0
loc
United States — Illinois is Abbott's home state, referenced as the company's base in coverage of the settlement.
Importance 10.0 Sentiment 0.0
per
The U.S. Attorney for the Western District of United States — Michigan stressed that infant formula manufacturers must meet regulatory and contractual requirements.
Importance 10.0 Sentiment 0.0
+ 1 more entities View on Dashboard
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.